Arcus Biosciences Crecimiento futuro

Future controles de criterios 1/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Arcus Biosciences de 15% y 21.8% por año respectivamente. Se prevé que el BPA crezca en un 21.7% al año. Se espera que la rentabilidad financiera sea de -213.7% en 3 años.

Información clave

11.8%

Tasa de crecimiento de los beneficios

17.3%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.5%
Tasa de crecimiento de los ingresos	12.1%
Rentabilidad financiera futura	-180.7%
Cobertura de analistas	Good
Última actualización	30 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth

Mar 20

What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You

Feb 23

Arcus Biosciences: Trading At Large Discount To Recent Gilead Investment

Feb 22

Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Dec 18

Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation

Aug 08

Arcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But Frustrates

Jun 15

Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk

May 05

Arcus Biosciences GAAP EPS of -$0.90 beats by $0.17

Nov 02

Analysts Just Slashed Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Numbers

May 12

Arcus Biosciences: Not Much Data Yet, But Gilead Deal Is A Huge Value Add

Jan 07

Forecast: Analysts Think Arcus Biosciences, Inc.'s (NYSE:RCUS) Business Prospects Have Improved Drastically

Nov 25

Analysts Just Shaved Their Arcus Biosciences, Inc. (NYSE:RCUS) Forecasts Dramatically

Aug 08

Need To Know: Analysts Are Much More Bullish On Arcus Biosciences, Inc. (NYSE:RCUS) Revenues

Jun 26

Previsiones de crecimiento de beneficios e ingresos

NYSE:RCUS - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	159	-348	-175	N/A	5
12/31/2025	164	-382	-302	N/A	9
12/31/2024	187	-325	-275	N/A	9
3/31/2024	237	-231	N/A	N/A	N/A
12/31/2023	117	-307	-330	-306	N/A
9/30/2023	120	-293	-306	-288	N/A
6/30/2023	121	-287	-316	-306	N/A
3/31/2023	119	-279	-326	-314	N/A
12/31/2022	112	-267	426	438	N/A
9/30/2022	433	80	426	446	N/A
6/30/2022	409	67	447	473	N/A
3/31/2022	392	58	439	464	N/A
12/31/2021	383	53	-282	-256	N/A
9/30/2021	38	-278	-263	-244	N/A
6/30/2021	93	-199	14	26	N/A
3/31/2021	85	-168	70	76	N/A
12/31/2020	78	-123	108	111	N/A
9/30/2020	78	-88	150	152	N/A
6/30/2020	15	-112	-93	-92	N/A
3/31/2020	15	-95	-89	-88	N/A
12/31/2019	15	-85	-75	-73	N/A
9/30/2019	7	-80	-73	-71	N/A
6/30/2019	9	-69	-58	-55	N/A
3/31/2019	9	-54	-50	-47	N/A
12/31/2018	8	-50	-47	-43	N/A
9/30/2018	8	-51	-24	-20	N/A
6/30/2018	4	-63	-36	-33	N/A
3/31/2018	3	-59	-33	-29	N/A
12/31/2017	1	-53	N/A	-25	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que RCUS siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que RCUS siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que RCUS siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (21.8% al año) de RCUS crezcan más rápidamente que los del mercado US (8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 12.1% al año) de RCUS crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: RCUS se prevé que no sea rentable en 3 años.

Arcus Biosciences Crecimiento futuro

Future controles de criterios 1/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates increase by 35%, EPS downgraded

Price target decreased by 7.9% to US$39.70

Price target decreased to US$50.10

Price target decreased to US$50.80

Consensus revenue estimates fall by 18%

Price target decreased to US$59.70

Recent updates

Arcus Biosciences, Inc. Reports Impairment of Long-Lived Assets for the First Quarter Ended March 31, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Arcus Biosciences, Inc., Annual General Meeting, Jun 06, 2024

Chief Operating Officer notifies of intention to sell stock

Chief Operating Officer recently sold US$241k worth of stock

We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth

Chief Operating Officer notifies of intention to sell stock

Consensus revenue estimates increase by 35%, EPS downgraded

What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Arcus Biosciences: Trading At Large Discount To Recent Gilead Investment

Price target decreased by 7.9% to US$39.70

Arcus Biosciences, Inc. Announces Data from A Phase 1B Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naive Metastatic Pancreatic Cancer

Co-Founder notifies of intention to sell stock

Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Co-Founder notifies of intention to sell stock

Arcus Biosciences: Showing There Might Be Something To TIGIT After All

Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?

Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announces New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers

Arcus Biosciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Insufficient new directors

COO & Director notifies of intention to sell stock

Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data

Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Arcus Biosciences, Inc. to Report Q2, 2023 Results on Aug 07, 2023

New minor risk - Shareholder dilution

Arcus Biosciences, Inc. announced that it expects to receive $19.4526 million in funding from Gilead Sciences, Inc.

COO & Director notifies of intention to sell stock

COO & Director recently sold US$243k worth of stock

COO & Director notifies of intention to sell stock

Arcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But Frustrates

Arcus Biosciences, Inc. Provides Updated Results from an Interim Analysis of ARC-7

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk

COO & Director recently sold US$147k worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Arcus Biosciences, Inc. to Report Q4, 2022 Results on Feb 28, 2023

COO & Director notifies of intention to sell stock

Investor sentiment improves as stock rises 17%

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announces Positive Results for the Fourth Interim Analysis of the ARC-7 Study in Patients

COO & Director recently sold US$507k worth of stock

Investor sentiment improved over the past week

Arcus Biosciences, Inc. Announces Positive Update from the Fourth Interim Analysis of ARC-7

Investor sentiment improved over the past week

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Arcus Biosciences GAAP EPS of -$0.90 beats by $0.17

Arcus Biosciences, Inc. to Report Q3, 2022 Results on Nov 02, 2022

COO & Director recently sold US$333k worth of stock

Price target decreased to US$50.10

Arcus Biosciences, Inc. Appoints Dimitry S.A. Nuyten as Chief Medical Officer

Price target decreased to US$50.80

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Arcus Biosciences, Inc. to Report Q2, 2022 Results on Aug 03, 2022

COO & Director recently sold US$272k worth of stock

Investor sentiment improved over the past week

Consensus revenue estimates fall by 18%

Price target decreased to US$59.70

Analysts Just Slashed Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Numbers

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new directors

Arcus Biosciences, Inc., Annual General Meeting, Jun 14, 2022

Consensus forecasts updated

Investor sentiment deteriorated over the past week